Actinium Pharmaceuticals (ATNM) Given a $3.00 Price Target by Maxim Group Analysts
A number of other analysts have also commented on ATNM. B. Riley set a $3.00 price objective on Actinium Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, December 27th. Zacks Investment Research upgraded Actinium Pharmaceuticals from a hold rating to a buy rating and set a $0.75 price objective for the company in a research report on Monday, December 25th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average price target of $3.75.
Actinium Pharmaceuticals (ATNM) opened at $0.36 on Tuesday. Actinium Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $1.68. The stock has a market capitalization of $32.44, a PE ratio of -0.77 and a beta of 40.64.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.